Retiro De Equipo (Recall) de Birmingham Hip Resurfacing (BHR) System

Según Department of Health, Therapeutic Goods Administration, este evento ( retiro de equipo (recall) ) involucró a un dispositivo médico en Australia que fue producido por Smith & Nephew Surgical Pty Ltd.

¿Qué es esto?

Una corrección al equipo o acción de retiro tomada por el fabricante para abordar un problema con un dispositivo médico. Los retiros (recalls) ocurren cuando un dispositivo médico está defectuoso, cuando puede poner en riesgo la salud, o cuando simultáneamente está defectuoso y puede poner en riesgo la salud.

Más información acerca de la data acá
  • Tipo de evento
  • ID del evento
  • Clase de Riesgo del Evento
    Class II
  • Fecha de inicio del evento
  • País del evento
  • Fuente del evento
  • URL de la fuente del evento
  • Notas / Alertas
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Notas adicionales en la data
  • Causa
    Smith & nephew has updated the instructions for use of the birmingham hip resurfacing (bhr) system to include an expansion of the warnings for certain population sub-groups, in line with available data sources including registry data. the ifu has been updated to note that: if a patient from the following population sub-groups is implanted with a bhr system, the patient is at greater risk of requiring a revision surgery earlier than expected: (a) females, (b) males aged 65 or greater, (c) patients requiring an implant head size =48m, (d) patients who have a diagnosis of avascular necrosis; and (e) patients who have congenital dysplasia. patients who experience symptoms including pseudotumors, tissue masses, fluid collections, enlarged bursae, pain and swelling, local buildup of excessive metal particles or metal hypersensitivity, may require revision surgery, with attendant risks and the potential for impaired function.
  • Acción
    Smith & Nephew is contacting all the implanting surgeons of Birmingham Hip Resurfacing (BHR) system to inform them of the changes to the IFU. Smith & Nephew is recommending the surgeons to use the BIRMINGHAM HIP Resurfacing System only after considering the warning statement and indications for use in the updated IFU attached. Smith & Nephew is further recommending to continue to apply standard practices for patient follow-up care. Smith & Nephew is forwarding the IFU's to two hospitals that have stock on hand. This action has been closed-out on 31/08/2016.


  • Modelo / Serial
    Birmingham Hip Resurfacing (BHR) SystemMultiple catalogue numbersAll batchesARTG numbers: 120078 & 124099
  • Manufacturer